Industry Outlook

The Smart Inhalers market accounted for USD 1.82 billion in 2024 and is expected to reach USD 8.2 Billion by 2035, growing at a CAGR of around 14.7% between 2025 and 2035. Smart Inhalers Market is a growing segment of the healthcare industry that is revolutionizing the treatment of respiratory diseases such as asthma and COPD. The smart inhalers market encompasses sophisticated inhalers that are integrated with technological innovation. These gadgets are featured with sensors that track drug intake, monitor external factors (air quality), and dispense real-time responses to users and medical professionals. Smart inhalers help to increase medication adherence by providing detailed data on inhaler usage patterns through smartphones. This can stop severe attacks and reduce the number of inpatient stays.

Report Scope:

Market Dynamics

Increasing adoption of connected health technologies

The growing adoption of healthcare technologies helps to drive the smart inhalers market. This technology allows real-time patient monitoring data. Devices like smart inhalers, wearables, and remote patient monitoring systems are empowering patients to manage chronic conditions more effectively. Technology makes it possible to remotely monitor the patient's health and assists medical professionals in making timely and accurate interventions.  Health technologies promote the patient's engagement by providing insights and advice on their health conditions. With the integration of IoT and AI, connected health solutions are becoming more accessible and intuitive, enhancing patient engagement and medication adherence.

Limited reimbursement policies for smart inhalers, hindering widespread adoption.

The limited reimbursement policies for the smart inhaler market led to a significant restraint for wide adoption. Due to inadequate insurance coverage, patients need to spend more on these devices. These financial problems restrict patients from using smart inhalers more than traditional inhalers. Healthcare providers also hesitate to prescribe smart inhalers for patients dependent on insurance. The complex and lengthy negotiations delay the market entry. The manufacturers are less motivated due to this complication.

Expansion into emerging markets with increasing healthcare infrastructure and awareness.

By improving healthcare infrastructure and increasing awareness, the smart inhalers market can expand into the emerging market. Improved healthcare system facilitates the smart inhaler integration and adoption. The campaigns and public initiatives help create awareness about smart inhalers. The growing disposable income in emerging markets is leading to a higher propensity among consumers to spend on healthcare. This increased financial capacity allows individuals to prioritize health-related products and services, driving demand for advanced medical technologies and improved healthcare access. Consequently, healthcare investments are rising, reflecting a broader shift toward proactive and preventative care.

Industry Experts Opinion

“This could be a real turning point for the way we help children with high-risk asthma in the UK. We know that many people with asthma struggle with taking their medication regularly as prescribed."

• Dr Erol Gaillard from the University of Leicester’s Department of Respiratory Sciences and University Hospitals of Leicester NHS Trust

“When you develop an infusion pump for use with a certain drug, you have to determine that it delivers the drug to the right tissues and that the patient receives the correct amount.”

• Peter Wirthschaft, PhD, senior manager, medical device/IVD consultant for global public health and safety organization NSF.

Segment Analysis

Based on the product type, the Smart Inhalers Market has been classified into Metered Dose Inhalers, Dry Powdered Inhalers, and Nebulizers. Metered-dose inhalers are dominant in inhaling equipment because of their demonstrated effectiveness and widespread utilization. Medicine is administered by MDIs in the form of a compressed aerosol, enabling accurate and punctual dosing with each consumption.

Based on the disease indication, the Smart Inhalers Market has been classified into Asthma, Chronic Obstructive Pulmonary Disease, and Other Respiratory Diseases. Chronic Obstructive Pulmonary Disease (COPD) is dominant in the respiratory disease market. Because of the increasing incidence and high prevalence of respiratory illness caused by aging population, smoking, and contaminants in the environment, the requirement for inhalation devices such as MDIs, DPIs, and nebulizers on the rise.

Regional Analysis

North America is the largest market for smart inhalers. The rapid advancements in technology and increased awareness about respiratory diseases drive the market growth in this region. This market benefits from the well-developed infrastructure. The increasing healthcare expenditure and technological advances drive the adoption of smart inhalers.

The Asia-Pacific region is the second-highest market for smart inhalers. The market is growing due to the increased investments in medical technology. The growing awareness about COPD conditions and government initiatives drive market growth. The trend toward personalized medicine boosts the demand for smart inhalers.

Competitive Landscape

The Smart Inhaler Market is highly competitive, including key players such as 3M Company, Adherium Limited, AptarGroup Inc., and AstraZeneca plc driving inventions. The 3M Company is renowned for its capacity to improve patient monitoring and adherence by integrating cutting-edge technologies into inhalers. Adherium Limited is a leader in enhancing asthma and COPD management through patient engagement and real-time monitoring tools, with a focus on digital inhaler technology. Smart inhalers from AptarGroup Inc. with advanced connectivity features enable data collection and personalized therapy adjustments. These businesses contend by offering services like real-time adherence tracking, data analytics, and mobile app integration, which enhance patient management and treatment efficacy.

Smart Inhalers Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In April 2024, Adherium declared that it obtained FDA approval to utilize its Hailie Smart inhaler in conjunction with AstraZeneca's Breztri and Airsupra inhalation devices. This clearance offers real-time insights by gathering data on medication usage and inhaler technique.
• In July 2023, Teva introduced its digitally enabled inhaler, the GoRespDigihaler, in the UK. Patients with COPD and asthma use it.
• June 2023: Teva Pharmaceuticals and Phil Inc., a life science product commercialization and patient access platform company, announced a partnership to start a new program that will make the Digihaler family of smart inhalers more accessible to manage asthma.

Report Coverage:

By Product Type

• Metered Dose Inhalers
• Dry Powdered Inhalers
• Nebulizers

By Disease Indication

• Asthma
• Chronic Obstructive Pulmonary Disease
• Other Respiratory Diseases

By Distribution Channel

• Hospital Pharmacies     
• Retail Pharmacies        
• Online Channels

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• 3M Company
• Adherium Limited
• AptarGroup Inc.
• AstraZeneca plc
• Boehringer Ingelheim
• Cognita Labs
• GlaxoSmithKline plc
• Novartis AG
• OPKO Health Inc.
• Propeller Health (ResMed)
• Sensirion AG
• Teva Pharmaceutical Industries Ltd.
• Vectura Group Limited (Philip Morris International Inc.)
• Cohero Health Inc.
• RYAH Medtech Inc.

Frequently Asked Questions (FAQs)